Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities

The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented treatment benefits being obtained for cancer patients, including improved patient survival. However, over half of the patients experience immune related adverse events (irAEs) or toxicities, which can be fatal, aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, John, Gandhi, Aesha, Gray, Elin, Zaenker, Pauline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874109/
https://www.ncbi.nlm.nih.gov/pubmed/36713389
http://dx.doi.org/10.3389/fimmu.2022.991433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874109/
https://www.ncbi.nlm.nih.gov/pubmed/36713389
http://dx.doi.org/10.3389/fimmu.2022.991433

Ejemplares similares